Avalo Therapeutics (AVTX) Gross Profit (2017 - 2024)
Avalo Therapeutics filings provide 8 years of Gross Profit readings, the most recent being -$465000.0 for Q3 2024.
- On a quarterly basis, Gross Profit fell 4127.27% to -$465000.0 in Q3 2024 year-over-year; TTM through Sep 2024 was -$96000.0, a 177.42% decrease, with the full-year FY2023 number at $640000.0, down 95.62% from a year prior.
- Gross Profit hit -$465000.0 in Q3 2024 for Avalo Therapeutics, down from -$343000.0 in the prior quarter.
- In the past five years, Gross Profit ranged from a high of $14.4 million in Q3 2022 to a low of -$534000.0 in Q2 2022.
- Median Gross Profit over the past 5 years was $276000.0 (2022), compared with a mean of $1.2 million.
- Biggest five-year swings in Gross Profit: skyrocketed 4183.08% in 2020 and later plummeted 4127.27% in 2024.
- Avalo Therapeutics' Gross Profit stood at $1.4 million in 2020, then tumbled by 114.46% to -$205000.0 in 2021, then surged by 234.63% to $276000.0 in 2022, then soared by 186.96% to $792000.0 in 2023, then plummeted by 158.71% to -$465000.0 in 2024.
- The last three reported values for Gross Profit were -$465000.0 (Q3 2024), -$343000.0 (Q2 2024), and -$80000.0 (Q1 2024) per Business Quant data.